|
Match
|
Document |
Document Title |
|
|
5342613 |
Pharmaceutical compositions and use thereof in the treatment of psoriasis
A pharmaceuticl composition and a method for its use in the treatment of psoriasis are provided wherein the composition comprises tumor necrosis factor as an active ingredient and at least one...
|
|
|
5334379 |
Cytokine and hormone carriers for conjugate vaccines
This invention pertains to immunogenic conjugates comprising a carbohydrate containing antigen or other antigen bound to or genetically fused with a cytokine, lymphokine, hormone or growth factor...
|
|
|
5312621 |
Method of treating fibrotic disorders
A novel method of treating fibrotic disorders in humans comprises the administration of a sufficient quantity of a composition containing a human alpha- or beta-interferon to raise the total...
|
|
|
5271931 |
Methods for increasing C1 inhibitor concentrations using interferon-gamma and/or interleukin-6
The present invention relates to the use of interferon and/or interleukin-6 to increase intravascular C1 inhibitor concentrations in patients exhibiting or at risk for a C1 inhibitor deficiency....
|
|
|
5270037 |
Use of interferon and a substance with an antimalarial activity for the treatment of malaria infections
The use of pharmaceutical compositions comprising at least one antimalarial active substance and an interferon, preferably interferon-gamma (IFN-γ), is disclosed. The pharmaceutical composition...
|
|
|
5266310 |
Stabilization of therapeutically active proteins in pharmaceutical preparations
This invention relates to pharmaceutical preparations for topical application containing one or more stabilized therapeutically active proteins and optional conventional excipients, carriers and...
|
|
|
5264208 |
Potentiation of tumor necrosis factor (TNF) of interferon B1 (IFN-B1) antiviral activities by an anti-cachexia agent
The present invention discloses the use of a anti-cachexia agent with an antiviral agent, preferably used as a therapeutic agent in the treatment of viral infections. The anti-cachexia agent acts...
|
|
|
5260056 |
Composition for enhancing biosynthesis of interferon
An organic germanium compound to be effectively used for curing AIDS or making AIDS asymtomatic in various forms is expressed by the following rational formula: ##STR1## wherein n is an integer of...
|
|
|
5236704 |
Controlled release formulation
A controlled release formulation which comprises a compound selected from the group consisting of organic acidic compounds and acid anhydrides or esters capable of generating one of the organic...
|
|
|
5234684 |
Method for the prevention and treatment of bovine mastitis
A method for treating or preventing mastitis in cows is disclosed. The method contemplates the intramammary injection of bovine interferon-gamma. Interferon-gamma can be administered prior to...
|
|
|
5230886 |
Tumor cell suppression
A method for treating a cancer includes administration of an endotoxin to a patient at least a portion of whose neoplastic cells express the CD14 surface receptor. The endotoxin can be administered...
|
|
|
5231176 |
Distinct family DNA encoding of human leukocyte interferons
This invention related to the discovery and production by recombinant DNA technology of a novel, distinct family of human leukocyte interferons, having a total amino acid residue number greater...
|
|
|
5219576 |
Collagen wound healing matrices and process for their production
Collagen implants that are useful as wound healing matrices are characterized by being formed of collagen fibrils that are not chemically cross-linked, and having a bulk density of 0.01 to 0.3 g/cm...
|
|
|
5215744 |
Methods for the treatment of tumors
Disclosed is a method of treating tumors capable of being treated with interferon by administering interferon and dipyridamole, or pharmaceutically acceptable salts thereof, in amounts sufficient...
|
|
|
5211945 |
Compositions and methods for modulating the effect of TNF and IL-1
This invention relates to methods for modulating the effects of TNF and IL-1, both the deleterious and the therapeutical effect of these cytokines. In case of deleterious effects, the invention...
|
|
|
5208019 |
Use of gamma-interferon for the treatment of vascular stenosis
The present invention relates to the use of gamma-interferon for the preparation of a pharmaceutical preparation for the treatment of vascular stenosis caused by e.g. intimal hyperplasia, including...
|
|
|
5196323 |
Process for preparing and purifying alpha-interferon
A process for the preparation and purification of recombinant Interferon-α is disclosed. The invention is directed to a process comprising the following steps: cultivating E. coli containing the...
|
|
|
5190751 |
Treatment of certain leukemias with a combination of gamma interferon and alpha interferon
Human leukemia T-cells and B-cells are inhibited from proliferating by treatment with a combination of recombinant human alpha and gamma interferons, either simultaneously or sequentially, and the...
|
|
|
5176921 |
Method of blood component decontamination by glucose addition
Biological compositions are freed of functional polynucletides by treatment of the biological composition with psoralen derivatives under irradiation conditions in which the proteins retain their...
|
|
|
5171567 |
Method for the treatment of ATLL and the inhalant for the same
An improved method for treating or curing ATL, with lowered side effects, comprising administering an effective amount of interferon-γ to a mammalian species in need of such treatment via...
|
|
|
5165921 |
Method for treating condyloma acuminatum with interferon
A pharmaceutical composition which includes human alpha-interferon, sodium dodecyl sulfate and a pharmaceutically acceptable vehicle is described. A method of using the pharmaceutical composition...
|
|
|
5141735 |
Substituted amino-benzodiazepines having anitviral activity
Novel substituted 2-amino-5-(1H-pyrrol-2-yl)-3H-1,4-benzodiazepines and compositions containing same for treatment and prophylaxis of viral infections, including HIV infections.
|
|
|
5128126 |
Use of pharmaceutical compositions containing at least one cytokine for the systemic treatment of preneoplastic lesions
The invention relates to the use of pharmaceutical compositions containing at least one cytokine for the systemic treatment of preneoplastic lesions. The pharmaceutical composition according to the...
|
|
|
5122372 |
Process for treatment of allergies
This invention relates to the immunotherapeutic treatment of allergies. More particularly, this invention relates to a process for treating allergies by administering to a mammal a pharmaceutically...
|
|
|
5122368 |
Anthracycline conjugates having a novel linker and methods for their production
The invention relates to anthracycline conjugates comprising at least one anthracycline molecule linked to a molecule that is reactive with a cell population to be eliminated such as antibody,...
|
|
|
5120535 |
Oncostatin M and novel compositions having anti-neoplastic activity
Novel compositions are provided for modulating growth, particularly of tumor cells, which compositions are combinations of Oncostatin M, and one or both of transforming growth factors or...
|
|
|
5120832 |
Distinct family of human leukocyte interferons
The discovery and production by recombinant DNA technology of a novel, distinct family of human leukocyte interferons, having a total amino acid residue number greater than 166, preferably about 172.
|
|
|
5116612 |
Immunotherapy agents for treatment of IgE mediated allergies
A protein conjugate or mixture useful in immunotherapy composed of a biological response modifier (BRM) and an allergen is disclosed. In use the protein conjugate or mixture is combined with a...
|
|
|
5116943 |
Oxidation-resistant muteins of Il-2 and other protein
A biologically active reference therapeutic protein is protected against oxidation by a method involving substituting a conservative amino acid for each methionyl residue susceptible to chloramine...
|
|
|
5114711 |
Covalently linked polypeptide cell modulators such as interferon-lymphotoxin conjugates
Described is a new class of polypeptide cell modulators characterized by being composed of two covalently linked cell modulators in a linear polypeptide sequence. Such dual function polypeptides...
|
|
|
5110604 |
Processes for producing collagen matrixes and methods of using same
Collagen implants that are useful as wound healing matrices are characterized by being formed of collagen fibrils that are not chemically cross-linked, and having a bulk density of 0.01 to 0.3 g/cm...
|
|
|
5108743 |
Method of treating primary cancers of the pleura
A method of treating primary cancers of pleura in warm-blooded animals having said cancers comprising administering to said warm-blooded animals an amount of a polypeptide having human gamma...
|
|
|
5093115 |
Method of preparing activated killer monocytes for treating colorectal cancer
The present invention discloses a method of preparing activated killer monocytes for treating colorectal cancer. Activated killer monocytes are prepared in serum free medium in polypropylene...
|
|
|
5071872 |
Method for improving interleukin-2 activity using aci-reductone compounds
A method for improving interleukin-2 induced lymphocyte killing of cancer cells comprises administering to a patient having cancer an effective amount of at least one aci-reductone compound...
|
|
|
5059418 |
Synergistic effect of human recombinant interferon-beta on halogenated pyrimidines
A method of treating patients having viral infections exhibiting a synergistic antiviral effect in combination therapy of viral infections is comprised of combining synergistically effective...
|
|
|
5055289 |
Interferon antibody therapeutic compositions having an extended serum half-life
A complex of alpha-interferon with a monoclonal antibody complexes with the alpha-interferon without impairing its antiviral activity. The serum half-life of the interferon administered as the...
|
|
|
5051408 |
Inulin compositions in gamma polymorphic form
A process for preparing gamma inulin comprising the steps of (a) recrystallizing crude inulin from water at a temperature below 37° C. to obtain a suspension, (b) heating the suspension at a...
|
|
|
5049378 |
Prevention and treatment of porcine haemophilus pneumonia (PHP)
Methods of treating diseases in swine are disclosed using porcine interferon alpha and/or gamma.
|
|
|
5045320 |
Large multivalent immunogen
Immunization and/or therapeutic in vivo introduction of ligands bound alone or in combination with other molecules, arrayed on solid supports having greater then about 0.2μ diameter to elicit and...
|
|
|
5041289 |
Method of purging residual tumor cells in vitro with lymphokine activated cytotoxic cells
A method is disclosed for removing residual tumor cells from a patient with a neoplastic disorder by treating in vitro cell preparation with lymphokine activated cytotoxic cells.
|
|
|
5028422 |
Treatment of basal cell carcinoma intralesionally with recombinant human alpha interferon
This invention relates to a method of treating basal cell carcinoma with purified human recombinant DNA interferon alpha-2, preferably purified human recombinant DNA interferon alpha-2b by...
|
|
|
5026544 |
Methods and compositions for inhibiting the growth of neoplastic cells
The present disclosure is directed to the use of combinations of a papaverine family member agent together with an interferon for the treatment of proliferative disorders such as neoplasias and...
|
|
|
5024833 |
Combined interferon/antiestrogen therapy for treatment of breast cancer
Proliferation of breast cancer is treated by a combined type I interferon/antiestrogen therapy. Preferably artiestrogen treatment is sequential to treatment with interferon.
|
|
|
5021241 |
Long-term sustained-release preparation
A solid sustained-release preparation in the form of a needle-like or bar-like shape, which consists essentially of an active ingredient and a pharmaceutically acceptable biodegradable carrier...
|
|
|
5019382 |
Treatment of immuno-resistant disease with low-dose interferon
Neoplastic disease, hyperallergenicity, autoimmune disorders characterized by chronic tissue degenerative inflammation and immuno-resistant viral infections are treated by the administration of...
|
|
|
5017371 |
Method for reducing side effects of cancer therapy
Low doses of interferon contacted with the oral and pharyngeal mucosa of a patient in conjunction with administration of radiation therapy or chemotherapy reduces the toxic side effects associated...
|
|
|
5002764 |
Treatment of actinic keratoses with alpha.sub.2 interferon
A method of treating actinic keratoses with alpha 2 interferon is disclosed.
|
|
|
4997646 |
Use of interferons of the alpha family to enhance fertility in mammals
A method for enhancing the fertility and for prolonging the lifespan of the corpus luteum in female mammals. The method comprising administering to the female mammal an effective amount of an...
|
|
|
4997645 |
Methods and pharmaceutical composition for the treatment of tumors
Disclosed is a method of treating tumors capable of being treated with interferon which is comprised of interferon and dipyridamole, or pharmaceutically acceptable salts thereof, in amounts...
|
|
|
4994556 |
Novel lymphokine and its production and uses
A novel lymphokine and its production and uses are disclosed. The lymphokine is a glycoprotein with a molecular weight of 15,000±2,000 daltons; isoelectric point pI, 4.5±0.5; electrophoretic...
|